386 results on '"Gonsalves, Wilson I."'
Search Results
2. Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders
3. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
4. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
5. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
6. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
7. Treatment‐responsive glycogen storage myopathy in a patient with POEMS syndrome: A new monoclonal gammopathy‐associated myopathy
8. Impact of Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas
9. Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti‐CD38 monoclonal antibody
10. Utility of flow cytometry screening before MRD testing in multiple myeloma
11. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
12. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
13. The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up
14. Monoclonal Gammopathy of Undetermined Significance
15. Sarcopenia identified by computed tomography imaging using a deep learning–based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma
16. Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
17. Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
18. Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma
19. Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis
20. Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
21. Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
22. Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
23. A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
24. Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
25. Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
26. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
27. The Effect of Glucagon on Protein Catabolism During Insulin Deficiency: Exchange of Amino Acids Across Skeletal Muscle and the Splanchnic Bed
28. Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care
29. Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
30. Sarcopenia identified by computed tomography (CT) imaging using a machine learning–based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM).
31. Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.
32. The Effect of Glucagon on Protein Catabolism During Insulin Deficiency - Exchange of Amino acids across Skeletal Muscle and the Splanchnic Bed
33. The Effect of Glucagon on Protein Catabolism During Insulin Deficiency - Exchange of Amino acids across Skeletal Muscle and the Splanchnic Bed
34. Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma
35. Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing
36. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
37. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
38. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
39. Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma
40. Melflufen for multiple myeloma: a promise unfulfilled?
41. Immunoglobulin Deposition Diseases
42. Plasma Cell Leukemia
43. Cryoglobulins and Cryoglobulinemia
44. Evolving progress in the management of malignant plasma cell disorders
45. Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States
46. Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab
47. "Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience
48. Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma
49. An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS)
50. Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.